Abstract

Transurethral resection of bladder tumors (TURBT) remains a vital diagnostic and early-stage treatment tool. Robotic-assisted radical cystectomy (RARC) demonstrates benefits over open surgery, including reduced blood loss and shorter hospital stays. Laparoscopic and endoscopic procedures, such as single-port and NOTES, show promise in select cases. Personalized medicine, driven by genomics and molecular profiling, enables tailored treatment strategies based on tumor characteristics. Collaborative efforts among urologists, oncologists, and other healthcare professionals are essential for optimizing patient outcomes. These advancements offer new prospects for improved prognosis and quality of life in bladder cancer patients.